Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: Results from an open-label study

British Journal of Dermatology

Volumn 167, Issue 3, 2012, Pages 658-667

  Leonardi, C ^a   Sobell, J M ^b   Crowley, J J ^c   Mrowietz, U ^d   Bao, Y ^e   Mulani, P M ^e   Gu, Y ^e   Okun, M M ^e  

^a Central Dermatology   (United States)

^b SKINCARE PHYSICIANS   (United States)

^c Bakersfield Dermatology   (United States)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PLACEBO;

ADULT; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMYELINATING DISEASE; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INFECTION; LUPUS LIKE SYNDROME; LYMPHOMA; MALE; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; SKIN CANCER; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; HUMANS; INJECTIONS; MALE; PSORIASIS; TREATMENT OUTCOME;

EID: 84865610880     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11041.x     Document Type: Article

References (16)

1. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
2. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15. (Pubitemid 350298146)
3. Croom KF, McCormack PL,. Adalimumab: in plaque psoriasis. Am J Clin Dermatol 2009; 10: 43-50.
4. Camp NJ, Slattery ML,. Classification tree analysis: a statistical tool to investigate risk factor interactions with an example for colon cancer (United States). Cancer Causes Control 2002; 13: 813-23. (Pubitemid 35305200)
5. Lemon SC, Roy J, Clark MA, et al. Classification and regression tree analysis in public health: methodological review and comparison with logistic regression. Ann Behav Med 2003; 26: 172-81. (Pubitemid 38001837)
6. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606. (Pubitemid 44436647)
7. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66. (Pubitemid 351239154)
8. Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat 2007; 18: 25-31. (Pubitemid 46410639)
9. Larian A, Emer JJ, Gordon K, et al. Efficacy and safety of a second adalimumab treatment cycle in psoriasis patients who relapsed after adalimumab discontinuation or dosage reduction: a double-blind, randomized, placebo-controlled trial. Psoriasis Forum 2011; 17: 88-96.
10. Gordon K, Blum R, Papp K, et al. Efficacy and safety of adalimumab treatment in patients with moderate to severe psoriasis: a double-blind, randomized clinical trial. Psoriasis Forum 2007; 13: 4-11.
11. Langley RG, Ellis CN,. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51: 563-9. (Pubitemid 39278075)
12. Revicki DA, Willian MK, Menter A, et al. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 2008; 216: 260-70. (Pubitemid 351416731)
13. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
14. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45. (Pubitemid 36091645)
15. Martyn-Simmons CL, Green L, Ash G, et al. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol 2009; 23: 1394-7.
16. Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007; 57: 269-75. (Pubitemid 47048857)